Eurofins launches new dedicated Global Central Laboratory in India
Sandra Hageman, Eurofins Global Central Laboratory, The Netherlands
Today, India has grown to become the global hub of outsourcing of clinical trials. The largest benefits India is offering to the pharmaceutical companies are India’s huge population of more than one billion, a great hospital infrastructure, very skilled English-speaking medical staff and most importantly, major cost reductions for conducting clinical trials. McKinsey & Co estimated that around $1-1.5 billion would be spent in 2010 just on drug trials in the country.
In September, Eurofins Global Central Laboratory achieved an important strategic milestone with the opening of a new laboratory site in Bangalore, India. Joining the existing Eurofins Food and Eurofins Genomics laboratory operations in technology hub Bangalore, Eurofins Global Central Laboratory has a clear focus on the Asia-Pacific region by deploying three wholly-owned central laboratories in Singapore, China and India. These laboratories go together with the central laboratories in the United States and Europe to create a true global footprint. The Bangalore facility operates like an extension of the other Eurofins central labs as all laboratory equipment, methods, operating procedures, LIMS and quality standards are identical.
The Bangalore facility’s location gives it easy access to the transportation infrastructure in India, enabling close control over transportation and maintenance of specimen integrity. The Sponsors can expect similar results in India, with the benefit of having a reduced cost because the clinical trial samples are no longer transported to either Europe or United States.
Contact: clinicaltrials@eurofins.com
